Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center studyShow others and affiliations
2014 (English)In: Dementia and Geriatric Cognitive Disorders, ISSN 1420-8008, E-ISSN 1421-9824, Vol. 38, no 3-4, p. 234-244Article in journal (Refereed) Published
Abstract [en]
AIMS: To examine the effects of galantamine and risperidone on agitation in patients with dementia.
METHODS: A total of 100 patients with dementia and neuropsychiatric symptoms (mean age ± SD: 78.6 ± 7.5 years; 67% female) were included in this 12-week, randomized, parallel-group, controlled, single-center trial. The participants received galantamine (n = 50; target dose: 24 mg) or risperidone (n = 50; target dose: 1.5 mg) for 12 weeks.
RESULTS: Both galantamine and risperidone treatment resulted in reduced agitation. However, risperidone showed a significant advantage over galantamine both at week 3 (mean difference in total Cohen-Mansfield Agitation Inventory score: 3.7 points; p = 0.03) and at week 12 (4.3 points; p = 0.01).
CONCLUSIONS: Agitation improved in both groups, even if the treatment effects were more pronounced in the risperidone group; however, the effects on cognition and other aspects of tolerability were stronger with galantamine.
Place, publisher, year, edition, pages
S. Karger, 2014. Vol. 38, no 3-4, p. 234-244
Keywords [en]
Neuropsychiatric symptoms, Agitation, Dementia, Behavioral and psychological symptoms of dementia, Galantamine, Risperidone
National Category
Neurology Geriatrics
Identifiers
URN: urn:nbn:se:oru:diva-74054DOI: 10.1159/000362204ISI: 000341445700010PubMedID: 24969380Scopus ID: 2-s2.0-84902912373OAI: oai:DiVA.org:oru-74054DiVA, id: diva2:1313965
2019-05-072019-05-072019-06-18Bibliographically approved